Sign Up Today and Learn More About NGM Biopharmaceuticals Stock

Invest in or calculate the value of your shares in NGM Biopharmaceuticals or other pre-IPO companies through EquityZen's platform.

Get Started

NGM Biopharmaceuticals Stock

NGM Biopharmaceuticals is a drug discovery company developing biotherapeutics for the gastrointestinal endocrine system.

About NGM Biopharmaceuticals Stock

Founded

2007

Headquarters

South San Francisco, CA, US

Total Funding

295M

NGM Biopharmaceuticals, Inc. is a privately held drug discovery company committed to identifying transformational medicines that dramatically improve human health. Based on emerging human clinical and genetic observations, the Company has devised several innovative experimental approaches to discover new therapies for the treatment of metabolic and cardiovascular diseases. Our current focus is on the gastrointestinal endocrine system, with an aim to identify novel factors implicated in the pathogenesis of type 2 diabetes and the apparent resolution of this grievous disease in patients who have undergone gastric bypass surgery.

NGM Biopharmaceuticals Press Mentions

Stay in the know about the latest news on NGM Biopharmaceuticals

NGM Biopharmaceuticals Management

Leadership team at NGM Biopharmaceuticals

Vice President, Research

Hui Tian

Vice President, Business Development

Aetna Wun Trombley

Locked Features

Join now and verify your accreditation status to gain access to:

  • NGM Biopharmaceuticals current valuation
  • NGM Biopharmaceuticals stock price
  • Available deals in NGM Biopharmaceuticals and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in NGM Biopharmaceuticals stock?

Accredited investors can buy pre-IPO stock in companies like NGM Biopharmaceuticals through EquityZen funds. These investments are made available by existing NGM Biopharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell NGM Biopharmaceuticals stock?

Shareholders can sell their NGM Biopharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 41K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."